Semaglutide vs Efpeglenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
Semaglutide is a GLP-1 receptor agonist, a peptide engineered to mimic the natural gut hormone GLP-1 but with a roughly week-long half-life so it can be dosed once weekly. It is FDA-approved and sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, with cardiovascular benefit also on the label. This is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides.
Also: Eppe, HM11260C
Efpeglenatide is a long-acting, once-weekly GLP-1 agonist from Hanmi Pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. Sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. Hanmi relaunched it for obesity, and on 7 October 2026 South Korea approved it as Eppe, the country's first homegrown GLP-1 obesity drug. It is not approved by the FDA or EMA.
Key Comparison Insights
- Semaglutide is FDA approved, while Efpeglenatide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to Efpeglenatide (Human Trials).
Detailed Comparison
| Attribute | Semaglutide | Efpeglenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide latches onto the GLP-1 receptor, the same receptor your own GLP-1 hormone uses after a meal. Activating it tells the pancreas to release more insulin when blood sugar is high, dials down glucagon (the hormone that raises blood sugar), and slows how fast the stomach empties, so you feel full longer. It also acts on appetite centers in the hypothalamus, which is the main reason it reduces hunger and drives weight loss. The molecule was modified with a fatty-acid chain that binds to albumin in the blood, which is the trick that stretches its half-life to about 160 hours and allows once-weekly injection. | Efpeglenatide activates the GLP-1 receptor, which raises insulin release after meals, lowers glucagon, slows stomach emptying and reduces appetite. The active part is an exendin-4 analog (the same parent peptide as exenatide and lixisenatide) attached through a small linker to a human IgG4 Fc fragment, using Hanmi's LAPSCOVERY platform. The Fc piece makes the molecule big enough to dodge kidney clearance and lets it recycle in the body, which stretches its half-life to weekly dosing. Hanmi argues its lower brain penetration explains the milder GI profile; that is a company argument rather than an independently proven fact. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | 10 mg once weekly maintenance (Korean label) Once weekly |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous auto-injector once weekly |
| Typical Duration | Long-term / chronic use | Long-term (chronic weight management); 40-64 weeks in the Korean phase 3 |
| Best Time to Take | Morning, same day each week | Same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The clinical evidence is extensive and high quality. The SUSTAIN program established blood-sugar control in type 2 diabetes, and SUSTAIN 6 showed a reduction in cardiovascular events. For obesity, the landmark STEP 1 trial (New England Journal of Medicine, 2021) randomized nearly 2,000 adults without diabetes and found mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo. In the head-to-head STEP 8 trial it beat liraglutide (15.8% vs 6.4%). The weight tends to come back after stopping: in the STEP 1 extension, people regained about two-thirds of the lost weight within a year off the drug. The SELECT trial (17,604 adults with heart disease and overweight or obesity but no diabetes) cut major cardiovascular events by 20%, which is the basis of Wegovy's cardiovascular indication (March 2024), and the FLOW trial underpins the kidney indication. Common side effects are gastrointestinal (nausea, vomiting, constipation), usually worst during dose escalation. Oral versions are approved too. Unlike most peptides discussed in research circles, semaglutide is a fully approved medicine with a deep, published evidence base. | The strongest data come from Sanofi's AMPLITUDE-O trial (NEJM 2021), which enrolled people with type 2 diabetes and cardiovascular or kidney disease. Efpeglenatide 4 or 6 mg weekly cut major cardiovascular events by 27% versus placebo (7.0% vs 9.2%, hazard ratio 0.73) over a median of 1.8 years, and also reduced kidney outcomes. Sanofi still returned the rights in 2020 for business reasons. Hanmi then ran a Korean phase 3 obesity trial in 448 adults without diabetes (average BMI 32): at 40 weeks, weight loss was 9.02% versus 0.89% on placebo, and 75.1% lost at least 5%. That is less weight loss than semaglutide or tirzepatide in their pivotal trials, though trial designs differ, and GI side effects were somewhat lower (diarrhea 17.6%, nausea 16.6%, vomiting 11.6%). Korea's MFDS approved it for chronic weight management on 7 October 2026, with launch planned for late October. Bottom line: a solid, proven drug class member with real outcome data, but modest weight loss and no Western approval. |
Frequently Asked Questions: Semaglutide vs Efpeglenatide
What is the difference between Semaglutide and Efpeglenatide?
Semaglutide is a weight loss peptide that semaglutide is a glp-1 receptor agonist, a peptide engineered to mimic the natural gut hormone glp-1 but with a roughly week-long half-life so it can be dosed once weekly. it is fda-approved and sold as ozempic and rybelsus for type 2 diabetes and as wegovy for chronic weight management, with cardiovascular benefit also on the label. this is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides. Efpeglenatide is a weight loss peptide that efpeglenatide is a long-acting, once-weekly glp-1 agonist from hanmi pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. hanmi relaunched it for obesity, and on 7 october 2026 south korea approved it as eppe, the country's first homegrown glp-1 obesity drug. it is not approved by the fda or ema. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or Efpeglenatide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while Efpeglenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and Efpeglenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and Efpeglenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.